Imugene MD & CEO Leslie Chong said “We are pleased with the results that we have seen so far in cohort 1 with no observed toxicity with early encouraging results in oncolytic virus infection and replication in the TNBC tumours. We look forward to continuing this study and reporting to the market of its progress.”
As I keep saying. Get your information from Leslie Chong. Straight from the horses mouth.
Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc, page-3
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.2¢ | 4.1¢ | $456.6K | 11.10M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 3248478 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 2261698 | 8 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |